With the newly created AbbVie (ABBV -0.93%) drawing so much of its revenue from a single source, many investors are worried about what the company will look like after January 2017, when Humira goes over its patent cliff. In this video, Motley Fool health-care bureau chief Brenton Flynn discusses AbbVie's dividend and whether it can really continue to grow. In particular, he explains why strong cash flow for the company over the next few years could very likely mean dividend growth.